White Plains R&D Tax Credit Explained for Businesses

R&D Tax Credits for White Plains, New York Businesses

White Plains, New York, is known for industries such as finance, healthcare, education, retail, and technology. Top companies in the city include Morgan Stanley, a leading financial services company; White Plains Hospital, a major healthcare provider; Pace University, a significant educational institution; The Westchester, a key player in the retail sector; and IBM, a prominent technology company. By reducing tax liability, businesses can reinvest in R&D, improve efficiency, and develop new products, enhancing their competitiveness and driving economic growth in White Plains.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 350 Northern Blvd, Albany, New York is less than 140 miles away from White Plains and provides R&D tax credit consulting and advisory services to White Plains and the surrounding areas such as: New Rochelle, Mount Vernon, Greenburgh, Hempstead and Oyster Bay.

If you have any questions or need further assistance, please call or email our local New York Partner on (518) 801-0616.
Feel free to book a quick teleconference with one of our New York R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

White Plains, New York Patent of the Year – 2024/2025

Acurx Pharmaceuticals Inc. has been awarded the 2024/2025 Patent of the Year for its innovation in targeted antibiotic therapy. Their invention, detailed in U.S. Patent No. 12036225, titled ‘Use of ibezapolstat to promote microbiome health’, outlines a new way to treat infections without disrupting the body’s natural gut microbiome.

The patented method uses ibezapolstat, a selective antibiotic that fights harmful bacteria like Clostridioides difficile while sparing beneficial microbes. This approach addresses a major limitation of traditional antibiotics, which often wipe out good bacteria along with the bad. By preserving microbiome balance, the treatment reduces the risk of recurring infections and supports long-term gut health.

Unlike broad-spectrum antibiotics, ibezapolstat targets specific bacterial enzymes, offering a more refined and sustainable option for patients. The innovation could be a game changer for managing antibiotic resistance and improving recovery outcomes in gastrointestinal infections.

Acurx Pharmaceuticals Inc. is leading the way in microbiome-friendly drug development. This patent not only protects a promising therapy but also marks a step forward in modern infectious disease treatment. As antibiotic stewardship becomes more critical, their work offers a solution that is both effective and mindful of overall health.